Trajenta tragedy drags on as G-BA bags gliptins that nipped in before
This article was originally published in Scrip
The G-BA, the body in charge of Germany's new and much maligned early benefit assessment, is to retroactively appraise drugs in the gliptin class that were already on the market before the healthcare reform law (AMNOG) came into force. This could be bad news for the drugs, including Merck's Januvia (sitagliptin), Novartis' Galvus (vildagliptin) and Eucreas (vildagliptin/metformin) as well as Bristol-Myers Squibb/AstraZeneca's Onglyza (saxagliptin). The drugs are likely to face the same hurdles that prompted Boehringer Ingelheim to withdraw its gliptin, Trajenta.